Neurology and Neurosurgery

Episodes 1-16 of 433

• 

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  RestartResume

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  NeuroFrontiers

  Bridging the Diagnostic Gap: Blood Biomarkers in Alzheimer’s Care

  • 

    

    Ashvini Keshavan, MRCP, PhD

• 

  RestartResume

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  RestartResume

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  NeuroFrontiers

  Bridging Inpatient to Outpatient Schizophrenia Care: Solutions for Safer Transitions

  • 

    

    Shelina Ramnarine, PhD

  • 

    

    Michelle Scargle, MD

  • 

    

    Margaret Emerson, DNP, APRN, PMHNP-BC

• 

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  RestartResume

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  Global Neurology Academy

  Negative Symptoms in Schizophrenia: Identifying and Managing the Hidden Burden

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Ahmed Makhlouf, MD

• 

  RestartResume

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  RestartResume

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  NeuroFrontiers

  Advancing Schizophrenia Care: When and How to Use Novel Therapies in Complex Patients

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Ragy R. Girgis, MD, MS

  • 

    

    Desiree Matthews, PMHNP-BC

• 

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  RestartResume

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  NeuroFrontiers

  Using fMRI to Identify Early Alzheimer’s Disease Subgroups

  • 

    

    Hamid Abuwarda, PhD, BS

• 

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  RestartResume

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  NeuroFrontiers

  Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease

  • 

    

    Sharon Sha, MD, MS

• 

  RestartResume

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  RestartResume

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  NeuroFrontiers

  Understanding Schizophrenia: The Role of Neurotransmission and Inflammation

  • 

    

    Jeffrey A. Lieberman, MD

• 

  RestartResume

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  RestartResume

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  NeuroFrontiers

  Harnessing AI to Predict and Prevent Schizophrenia Relapse

  • 

    

    Matcheri S. Keshavan, MD

• 

  RestartResume

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  RestartResume

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  NeuroFrontiers

  Engaging Patients and Caregivers in Schizophrenia: A Collaborative Care Approach

  • 

    

    Shelina Ramnarine, PhD

  • 

    

    Apurva Bhatt, MD

  • 

    

    Shannon Pagdon, BA

• 

  RestartResume

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  RestartResume

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  NeuroFrontiers

  Applying CBT for Psychosis in Schizophrenia Care: Strategies for Expanding Access

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    David Kimhy, PhD

• 

  RestartResume

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  RestartResume

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  Project Oncology®

  Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies

  • 

    

    Alexandria May, PharmD, BCPS

  • 

    

    Angela Waanders, MD, MPH, MS

  • 

    

    Ashley S. Margol, MD, MS

• 

  RestartResume

  Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy

  RestartResume

  Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy

  Clinician's Roundtable

  Improving Survival and Function in Pediatric TK2d with Nucleoside Therapy

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Caterina Garone, MD, PhD

• 

  RestartResume

  Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency

  RestartResume

  Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency

  Clinician's Roundtable

  Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Cristina Domínguez González, MD, PhD

• 

  RestartResume

  Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study

  RestartResume

  Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study

  Clinician's Roundtable

  Understanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Philip Yeske, PhD

• 

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  RestartResume

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  NeuroFrontiers

  Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices

  • 

    

    Sheetal Shroff, MD

• 

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  RestartResume

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  NeuroFrontiers

  Timing Meningococcal Vaccines in gMG: Challenges and Considerations

  • 

    

    Michael Weiss, MD

• Prev
• 1
• 2
• 3
• …
• 27
• 28
• Next